BRPI0720105A2 - Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos - Google Patents

Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Info

Publication number
BRPI0720105A2
BRPI0720105A2 BRPI0720105-2A2A BRPI0720105A BRPI0720105A2 BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2 BR PI0720105 A BRPI0720105 A BR PI0720105A BR PI0720105 A2 BRPI0720105 A2 BR PI0720105A2
Authority
BR
Brazil
Prior art keywords
amino acid
same
standard amino
amphtamine
manufacture
Prior art date
Application number
BRPI0720105-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Travis C Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BRPI0720105A2 publication Critical patent/BRPI0720105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0720105-2A2A 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos BRPI0720105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86937506P 2006-12-11 2006-12-11
PCT/US2007/087028 WO2008073918A1 (en) 2006-12-11 2007-12-10 Non-standard amino acid conjugates of amphetamine and processes for making and using the same

Publications (1)

Publication Number Publication Date
BRPI0720105A2 true BRPI0720105A2 (pt) 2014-10-07

Family

ID=39512105

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720105-2A2A BRPI0720105A2 (pt) 2006-12-11 2007-12-10 Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos

Country Status (11)

Country Link
US (3) US7776917B2 (enExample)
EP (1) EP2101571B1 (enExample)
JP (1) JP2010512413A (enExample)
CN (1) CN101594778A (enExample)
AT (1) ATE509622T1 (enExample)
AU (1) AU2007333105A1 (enExample)
BR (1) BRPI0720105A2 (enExample)
CA (1) CA2672138A1 (enExample)
ES (1) ES2364865T3 (enExample)
IL (1) IL198930A0 (enExample)
WO (1) WO2008073918A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
ES2364865T3 (es) * 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine
DE102007037478B3 (de) 2007-08-08 2008-04-30 Leifheit Ag Wäschetrockenständer
US8614346B2 (en) 2009-06-19 2013-12-24 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
US8779191B2 (en) 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
JP5976111B2 (ja) * 2011-07-28 2016-08-23 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
EP2739140A4 (en) * 2011-07-29 2015-06-03 Shire Llc PRODRUGS OF HOMOARGININE AND / OR CONJUGATES OF AMPHETAMINES AND OTHER STIMULANTS AND METHODS OF MAKING AND USING SAME
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
WO2014058742A1 (en) 2012-10-09 2014-04-17 Sears Douglas Therapeutic treatment
GB2545368B (en) 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
BR112019011640B1 (pt) 2016-12-11 2021-08-17 Kempharm, Inc Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
CA3059781A1 (en) * 2017-04-10 2018-10-18 Shire Pharmaceuticals Inc. Methods of treatment using an amphetamine prodrug
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CA3078418A1 (en) * 2017-10-06 2019-04-25 Instituto De Medicina Molecular Joao Lobo Antunes Treatment of obesity-related conditions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2019199731A1 (en) * 2018-04-10 2019-10-17 Shire Pharmaceuticals Inc. Amphetamine prodrug and crystalline froms thereof
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2020181000A1 (en) * 2019-03-06 2020-09-10 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
WO2021119316A1 (en) 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer
TW202309004A (zh) * 2021-08-24 2023-03-01 美商精神醫學公司 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE539185A (enExample) * 1954-06-28
US2881113A (en) * 1957-01-29 1959-04-07 Ortho Pharma Corp Therapeutically active compositions containing amphetamines
US2892753A (en) * 1957-02-26 1959-06-30 Boehringer Sohn Ingelheim Central nervous system stimulant
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
SI1041987T1 (sl) * 1997-12-22 2006-10-31 Euro Celtique Sa Farmacevtska oralna dozirna oblika, ki obsega kombinacijo opioidnega agonista in naltreksona
WO2001013921A1 (en) * 1999-08-23 2001-03-01 Ockert David M Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
CA2411564A1 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP1531844B1 (en) * 2002-02-22 2014-08-20 Shire LLC Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
EP1644019B2 (en) 2003-05-29 2018-02-21 Shire LLC Abuse resistant amphetamine compounds
US20080234206A1 (en) 2005-09-13 2008-09-25 Shire Llc Prodrugs of Phentermine
ES2364865T3 (es) * 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2433655A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine

Also Published As

Publication number Publication date
WO2008073918A1 (en) 2008-06-19
AU2007333105A1 (en) 2008-06-19
US20090234018A1 (en) 2009-09-17
ES2364865T3 (es) 2011-09-15
EP2101571A1 (en) 2009-09-23
JP2010512413A (ja) 2010-04-22
EP2101571A4 (en) 2010-01-13
US7776917B2 (en) 2010-08-17
US8101661B2 (en) 2012-01-24
EP2101571B1 (en) 2011-05-18
US20080139653A1 (en) 2008-06-12
US20100292336A1 (en) 2010-11-18
ATE509622T1 (de) 2011-06-15
HK1131518A1 (en) 2010-01-29
IL198930A0 (en) 2010-02-17
CN101594778A (zh) 2009-12-02
CA2672138A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
BRPI0720105A2 (pt) Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
WO2008098151A3 (en) Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0812877A2 (pt) " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ".
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
NO20092611L (no) Krystallinsk faststoff Rasagilin base
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
TW200621313A (en) Pharmaceutical compositions
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
WO2008051539A3 (en) Processes for preparing palonosetron salts
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
ATE552832T1 (de) Antidepressivum-propharmaka
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
BRPI0619018A2 (pt) composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, uso de um composto, e, composição
NL1031705A1 (nl) Aminozuurderivaten.
WO2006078984A3 (en) Uses of methylphenidate derivatives
CL2007003403A1 (es) Compuestos derivados de pirazol; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso para tratar asma, enfermedad obstructiva cronica, bronquitis, entre otras.
BRPI0816800A2 (pt) Composto, composição farmacêutica, e, uso de um composto.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: KEMPHARM, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.